empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases all-cause mortality
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Empagliflozin reduced all-cause mortality (OR: 0.47, 95% CI: 0.29-0.78, p = 0.004) and cardiovascular death (OR: 0.56, 95% CI: 0.38-0.82, p = 0.003) compared to placebo.”
Quoted verbatim from Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Adults with acute heart failure; pooled randomised placebo-controlled trials
Effect 0.47 odds ratio, 95% CI 0.29 to 0.78
Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.2025PMID:40324865Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against All-cause mortality
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45EE0BHSD3CDC9BWHYEK5BT